All Satellite Symposia, Presentation Theaters, and Learning Lounges preceding and following the official program IDWeek 2016 are independently organized and executed. IDWeek does not endorse or support the programming of any Symposia, Presentation Theater, or Learning Lounge.
Thomas Lodise, PharmD, PhD
Albany College of Pharmacy and Health Sciences
Department of Pharmacy Practice
Paul Tulkens, MD, PhD
Cellular and Molecular Pharmacology
& Center of Clinical Pharmacy
Louvain Drug Research Institute
Université catholique de Louvain
Third Faculty to be confirmed
- Identify and understand the clinical impact of resistant organisms including Gram Negative, Gram Positive and Mixed infections in order to optimize treatment strategies for ABSSSI through the selection of an appropriate agent for the suspected or confirmed pathogen.
- Appreciate the host’s role in the response to both the infection and the antibiotic through the exploration of challenging patients with ABSSSI that present with host factors such as co-morbidities, weight, age, concomitant diseases, medical or surgical intervention.
- Understand currently available and emerging pipeline treatment options for serious infections and how their profile along with specific host factors may impact the current treatment paradigm with the potential of driving improved patient outcomes.
- Account for current hospital economics in the treatment of ABSSSI including continuity of care, LOS, re-admission rates when making treatment decisions.
Center for Education Development designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™, 2.0 ANCC credits, or 2.0 CPE credits (UAN #0498-0000-16-008-L01-P).
Agenda subject to change and was provided by:
The Center for Education Development; 601 Route 206, 26-409; Hillsborough, NJ; 908-617-0177; Activitymanager@CEDevelopment.org.